牛痘的TY - T1的血栓性并发症tion against SARS-CoV-2: what pharmacovigilance reports tell us – and what they don't JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01111-2021 SP - 2101111 AU - Konstantinides, Stavros Y1 - 2021/01/01 UR - //www.qdcxjkg.com/content/early/2021/04/19/13993003.01111-2021.abstract N2 - In the present issue of the Journal [1], Smadja et al. present an analysis of global pharmacovigilance reports of thrombotic events following severe acute respiratory distress syndrome coronavirus (SARS-CoV)-2 vaccination. More specifically, the authors analysed the data entered into the World Health Organization (WHO) Global Database for Individual Case Safety Reports (VigiBase) between December 13, 2020 and March 16, 2021, covering, at that time, a population of almost 362 million vaccinated individuals across the world. The study focuses on three of the coronavirus disease (COVID)-19 vaccines available to date, namely the Pfizer-BioNtech (BNT162b2), Moderna (mRNA-1273), and OxfordAstraZeneca (ChAdOx1 nCov-19) vaccine. The study by Smadja et al. confirms the rarity of possible thrombotic complications in association with COVID-19 vaccination, reporting only 0.21 [95% CI 0.19–0.22] cases of thrombotic events per million person vaccinated-days. However, there were also some unexpected observations which deserve closer attention and cautious interpretation.Thrombotic complications of COVID-19 vaccination are very rare, but awareness is needed.The work of Stavros Konstantinides was supported by the German Federal Ministry of Education and Research (BMBF 01EO1003 & 01EO1503). The author is responsible for the contents of this publication. ER -